Clinical Study on Thymus-Kidney Transplantation From Neonatal Donors for the Induction of Immune Tolerance

Inclusion Criteria: 1. Recipients of both thymus and kidney transplants from the same donor. 2. Age between 18 and 65 years. 3. Non-solid organ combination transplant recipients (including heart-kidney or liver-kidney transplants, except thymus). 4. ABO blood type compatibility with the donor. 5. Negative donor-specific antibody (DSA). 6. Negative lymphocyte crossmatch (CDC). 7. Normal cardiac function (confirmed through ECG and echocardiograms). 8. Normal liver function. 9. Bodyweight between 40-100 kg (inclusive). 10. Evidence of prior epstein-barr virus (EBV) infection with positive EBV-specific immunoglobulin G (IgG) and negative immunoglobulin M (IgM). 11. Signed informed consent form. 12. Ability to adhere to regular follow-ups. 13. Normal hematopoietic function. Exclusion Criteria: 1. Clinically significant genital or urinary tract dysfunction. 2. Underlying kidney diseases with a high risk of recurrence in the transplanted kidney, including: * a. Focal segmental glomerulosclerosis (FSGS). * b. Type I or II membranoproliferative glomerulonephritis. * c. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP). 3. Any genetic mutation-associated diseases. 4. Presence of infectious diseases: 5. Strongly positive panel reactive antibodies (PRA). 6. History of receiving blood transfusion therapy. 7. Any other conditions that, in the investigator's opinion, are incompatible with participation in the trial.